Johnson & Johnson vs. Ultragenyx Pharmaceutical Inc.
Johnson & Johnson (JNJ) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| JNJ | RARE | |
|---|---|---|
| Market Cap | $653.61 billion | $1.43 billion |
| Revenue (TTM) | $97.93 billion | $717.21 million |
| Net Income (TTM) | $21.04 billion | $-585,969,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | RARE | |
|---|---|---|
| P/E Ratio | 31.59 | — |
| Price / Book | 7.69 | -4.91 |
| Price / Sales | 6.67 | 1.99 |
RARE leads on 2 of 2 valuation factors.
Profitability
| JNJ | RARE | |
|---|---|---|
| Net Margin | 21.48% | -81.70% |
| Return on Equity | 24.76% | 201.36% |
JNJ and RARE split the profitability factors evenly.
Dividend
| JNJ | RARE | |
|---|---|---|
| Dividend Yield | 1.97% | — |
| Payout Ratio | 62.18 | — |
JNJ and RARE split the dividend factors evenly.
Risk & Sentiment
| JNJ | RARE | |
|---|---|---|
| Short Interest | 0.67% | 5.60% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, RARE overview, RARE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.